*Dear editor*,

We read with the interest the recent paper by Chen *et al.* who described the clinical progression of 249 patients with coronavirus disease 2019 (COVID-19).[@bib0001] As the author mentioned, some factors, such as age and CD4 T cell counts, would be associated with intensive care units (ICU) admission. In addition, the application of host-directed therapy and early control of viral replication might be crucial for improving the prognosis of COVID-19. We are interested in investigating the potential risk factors associated with the progression and prognosis of COVID-19. To date, cases of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) and influenza A co-infection have been reported in COVID-19 patients.[@bib0002], [@bib0003], [@bib0004] We suspected that the recent infection with influenza among COVID-19 patients might affect disease prognosis and progression to some extent. The high specificity and the sensitivity of Immunoglobulin M (IgM) assays suggest that IgM is a reliable biomarker for the surveillance of recent influenza infection.[@bib0005] ^,^ [@bib0006] Here, we reported that recent infection of influenza A/B and produce specific IgM in COVID-19 might be a common phenomenon, and influenza IgM status could be the significant factor associated with clinical outcomes and prognosis of COVID-19.

For this retrospective study, the 1386 COVID-19 patients were hospitalized between 18 January and 26 April 2020 at Tongji Hospital in Wuhan, China. All patients were pathogen-confirmed COVID-19 cases and accepted serological influenza A/B IgM antibody tests upon admission. SARS-CoV-2 infection was confirmed by reverse transcriptase polymerase chain reaction assay (RT-PCR), and the methods were consistent with other studies.[@bib0007] The influenza A/B IgM antibody tests were conducted by indirect immunofluorescence assay (IIFA) of specific IgM antibodies (EUROIMMUN, FI 2821-17M, Germany). All operations were carried out according to the provided instructions.

The patients analyzed in this study were not vaccinated against influenza A/B at the time of admission. In our study, severe COVID19 cases were defined as oxygen saturation of 94% or less while breathing ambient air or needing oxygen support, consistent with the report of Ohmagari *et al*. [@bib0008] The Ethical Committee of Tongji Hospital approved the study. Informed consent was not obtained because this retrospective study was analyzed anonymously.

We performed a retrospective analysis on 1386 confirmed COVID-19 patients with influenza A/B IgM antibody test results. In total, 88.8% (1231/1386) of patients survived and 11.2% (155/1386) of patients died. More than half of patients (60.8%, 842/1386) were identified as severe cases, and 39.3% (544 of 1386) were classified as non-severe. According to patients' specific IgM status, influenza A IgM positive (A IgM^+^) or negative (A IgM^−^) and influenza B IgM positive (B IgM^+^) or negative (B IgM^−^), the patients were divided into three categories: A IgM^−^/ B IgM^−^ group (47.6%, 660/1386), A IgM^+^/ B IgM^−^ group (47.5%, 659/1386), and A IgM^−^/ B IgM^+^ group (4.8%, 67/1386). The A IgM^+^/ B IgM^+^ group was not included as we identified no such cases. In [Figure 1](#fig0001){ref-type="fig"} , in terms of the clinical outcome, the mortality rates of the A IgM^+^/ B IgM^−^ group and A IgM^−^/ B IgM^+^ group were lower than that of the A IgM^−^/ B IgM^−^ group. [Figure 1](#fig0001){ref-type="fig"} also indicates that the A IgM^−^/B IgM^−^ group had the highest rate of severe cases among the three groups. Statistically significant differences existed across the different groups when considering mortality (*P* = 0.0008) and severe illness rates (*P* \< 0.0001).Figure 1The clinical outcomes and the rate of severe illness among different influenza A/B IgM status groups. Abbreviations: A IgM: influenza A IgM; B IgM: influenza B IgM.Figure 1

To further explore the relationship between the influenza A/B IgM status and clinical outcome and illness severity among the COVID-19 patients, we established univariate analysis and multivariate analysis models ([Table 1](#tbl0001){ref-type="table"} ). For the univariate analysis, we found that sex, age, and comorbidities were significant cofactors among mortality and severe illness. The A IgM^+^/ B IgM^−^ group has showed lower risk of mortality (OR =0.514, 95%CI: 0.360--0.732) and severe illness (OR =0.511, 95% CI:0.408--0.640). For multivariate analysis, after adjustment for cofactors, patients in the A IgM^+^/ B IgM^−^ group were less likely to die than patients in the A IgM^−^/ B IgM^−^ group (OR = 0.671, 95% CI: 0.463--0.973). However, the mortality rate of the A IgM^−^/ B IgM^+^ group was not statistically different from that of the A IgM^−^/ B IgM^−^ group according to the adjusted model (OR = 0.903, 95% CI: 0.359--2.272). Furthermore, our analysis also indicated that a similar trend was also observed in severe/non-severe analysis. The A IgM^+^/B IgM^−^ group had a lower rate of severe illness than the A IgM^−^/B IgM^−^ group (OR = 0.601, 95% CI: 0.476--0.760), whereas no such difference was found for the A IgM^−^/B IgM^+^ group (OR = 0.968, 95% CI: 0.563--1.665).Table 1Univariate and multivariate analysis of risk factors of Death vs. Discharged or Severe vs.Non-severe.[a](#tb1fn1){ref-type="table-fn"}Table 1Variables\[n(%)\]Death vs. Discharged \[OR (95%CI)\]Severe vs. Non-severe \[OR (95%CI)\]Died (n=155)Discharged (n=1231)Non-severe (n=544)Severe (n=842)Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis**Sex** Male104 (14.9)596 (85.1)251 (35.9)449 (64.1)REFREFREFREF Female51 (7.4)635 (92.6)293 (57.3)393 (42.7)**0.460 (0.323-0.655)0.458 (0.316-0.662)0.750 (0.604-0.931)0.753 (0.599-0.946)Age (mean \[SD\])**69.6 (12.2)57.1 (15.7)53.5 (16.4)61.7 (14.6)**1.069 (1.054-1.085)1.067 (1.050-1.083)1.035 (1.027-1.042)1.035 (1.027-1.043)Comorbidities** No64 (8.3)708 (91.7)324 (42.0)448 (58.0)REFREFREFREF Yes91 (14.8)523 (85.2)220 (35.8)394 (64.2)**1.925 (1.371-2.702)**1.154 (0.803-1.658)**1.295 (1.041-1.611)**0.863 (0.677-1.100)**Influenza A/B IgM status groups**A IgM^−^/ B IgM^−^96 (14.6)564 (85.5)207 (31.4)453 (68.6)REFREFREFREFA IgM^+^/ B IgM^−^53 (8.0)606 (92.0)311 (47.2)348 (52.8)**0.514 (0.360-0.732)0.671 (0.463-0.973)0.511 (0.408-0.640)0.601 (0.476-0.760)**A IgM^−^/ B IgM^+^6 (9.0)61 (91.0)26 (38.8)41 (61.2)0.578 (0.243-1.374)0.903 (0.359-2.272)0.721 (0.429-1.210)0.968 (0.563-1.665)[^2]

In the analysis, older age, male gender, and comorbidities were more prone to poor outcomes and progression, which were consistent with previous studies.[@bib0001] ^,^ [@bib0009] Therefore, in the multivariate analysis, we adjusted these cofactors. We found that COVID-19 patients positive for influenza A IgM had a lower risk of mortality and severe illness compared with those showing negative A/B IgM status. However, these trends were not significant differences between A IgM^−^/ B IgM^+^ group and A IgM^−^/ B IgM^−^ group.

The reason for better prognosis and clinical outcome in influenza A IgM^+^ COVID-19 patients is likely complicated, but could be due to potential interactions between influenza A and SARS-Cov-2, or because IgM^+^ is a marker of patient functional immune status. However, the second hypothesis cannot fully explain why these protective effects were not observed among influenza B IgM^+^ COVID-19 patients. Due to the suddenness of the COVID-19 pandemic outbreak, more studies are needed to confirm these findings.

In summary, our results showed that recent influenza A/B infection in confirmed COVID-19 patients might be a common phenomenon. Moreover, we also observed that COVID-19 patients positive for influenza A IgM showed a lower risk of mortality and severe illness compared with those showing negative A/B IgM status. In contrast, this trend was not observed in influenza B IgM^+^ patients.
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